Biosimilar Index answers your questions, such as...
There are 15 biosimilar and non-comparable biologic (NCB) versions of bevacizumab (Avastin; Roche) in clinical development; with the Biosimilar Index you can know who is developing them, in which indications and what stage they’re at
Biosimilars and NCBs are being developed across 13 discreet therapy areas; investigate what are they and which areas dominate
There are 40 biosimilar and NCB programmes in Phase III trials; benefit from knowing who is developing them and what reference products are being targeted
There are 115 monoclonal antibodies out of a current total of 385 products in Biosimilar Index; make sure you know what classes of drug the other 270 are being developed for
Rituximab (Rituxan/MabThera; Roche) is top of the biosimilar and NCB development league, with over 30 individual programmes around the globe
If you need to track developments in the global biosimilar sector then this comprehensive service is all you need.
The prospect of a biosimilars market has been long in development and is now on the cusp of delivering real value as high-value brands lose patent protection.
Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.
A new force in biosimilar and NCB drug and market tracking
FirstView’s Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.
Two class beating services in one subscription!
Biosimilar Index: Pipeline Database
Updated as new market information becomes available, this Database provides up-to-date insight of over 380 (and growing) biosimilar and NCB drugs in development from over 130 companies worldwide. The Database can be downloaded (as often as you need) in MS Excel™ format.
Biosimilar Index: Landscape Review
Published quarterly and delivered by email in MS PowerPoint™, the Landscape Review is packed with slides of tables and charts on key reference medicinal product data, current and future market milestones, extensive product-by product reviews and relevant clinical trial activity. The Landscape Review is based on the updated research in the Biosimilar Index: Pipeline Database and enhanced by critical insights from in house and external biosimilar experts.
A service for the whole industry
Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.
With Biosimilar Index you can...
Understand the biosimilar and NCB development landscape through comprehensive coverage of the pipelines of all major biosimilar developers worldwide
Drill down to discover the levels of potential biosimilar competition by therapy area, drug class status and geography
Establish the level of biosimilar competition for leading biologic brands
Learn which biosimilar developers are potential future competitors or collaborators
Identify the biosimilar and NCB portfolios of over 130 companies and discover the leaders in product development for which products/therapy areas
Know where the development hotspots are and what research is taking place.
The Biosimilar Index is feature rich...
Includes both structured data and commercial interpretation
The Biosimilar Index: Pipeline Database covers all significant biosimilar products and is updated daily. Available 24/7 in MS Excel™ with unlimited downloads which can be incorporated into your own analytics package or visualisation software
The Biosimilar Index: Landscape Review provides and insightful quarterly analysis which identifies the developments that are really important
Biosimilar Index is Informed by a wide-range of respected sources with expert internal and external inputs and oversight
Biosimilar Index: Pipeline Database
The Biosimilars Index: Pipeline Database is checked daily. When a significant event happens, the database is updated, thereby ensuring you’re up to date with current market dynamics. The database is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included. Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the database enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies
Essential details covered in the database include:
Brand name(s) of reference
Indications and reported sales for the reference product
Biosimilars development company
HQ location of development company
Mode of application and route of administration
Clinical trials status
Global marketing status
Marketing agreements and licensing opportunities
Powerful data with intuitive analysis tools
With Biosimilars Index: Pipeline Database at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.
Biosimilar Index: Landscape Review
What’s hot and what’s not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important. Published quarterly, the Review is based on the daily-updated research in the Biosimilar Index: Pipeline Database, enhanced by critical insights and understanding from biosimilars experts.
The benefits and features of the Biosimilar Index: Landscape Review...
Includes essential structured data including
Sales data for reference products
Current and future market milestones
Individual single view analysis for leading products
Clinical trial activities and flow charts of development phase.
The service draws on a wide-range of reliable information sources such as clinical trial registries, company communications, conference proceedings, broker analysis and social media.
Includes powerful interpretation and analysis by knowledgeable experts to ensure that developments are scrutinised and the implications highlighted.
Presented in MS PowerPoint™ to bring clarity to the extensive charting and tables provided which can be incorporated into your own presentations.
Reasons to Purchase
Duncan Emerton, Senior Director Syndicated Insights and Analytics
FirstView’s Biosimilar Index is headed up by Dr Duncan Emerton, a recognised expert in the biosimilar field.
With over 15 years clinical research and commercial analysis experience gained with Pfizer and Datamonitor, Duncan brings a unique and informed perspective to the expanding market for biosimilars and the commercial, clinical and regulatory challenges it faces.
Duncan is a regular presenter and Chair at biosimilar-focused conferences and has contributed several acclaimed articles and book chapters on key issues including lifecycle management, profitability, commercialisation and strategy.
Innovation is the life blood of the industry, yet the cost of developing and bringing new products to market is spiralling. In a series of hard-hitting reports and tracking services, FirstView will forensically examine and answer fundamental questions such as:
As products are better able to target specific conditions, or sub conditions, then the patient pool can be small. How can industry and regulators bring new products to market that are affordable?
Is the current Phase trial system past its sell by date?
Will personalised medicine ever delivery on its promise?
Are biosimilars set for boom or bust?
“Beyond the Pill” – what’s your strategy?
Value-based pricing – who gains, who loses?
The pharmaceutical industry is on the verge of significant change: the old model simply doesn’t work and is unaffordable to industry and payers alike.
Make sure you understand the strategic implications and trends of these upcoming changes with FirstWord’s FirstView Reports!